The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients

详细信息    查看全文

• 作者：Sharon Seth ; MD ; ^{sharonjd111@gmail.com} ; David A. Khan ; MD
• 关键词：Chronic urticaria ; Angioedema ; Alternative agents ; Dapsone ; Sulfasalazine ; Hydroxychloroquine ; Tacrolimus ; Mycophenolate
• 刊名：The Journal of Allergy and Clinical Immunology: In Practice
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：5
• 期：1
• 页码：165-170.e2
• 全文大小：275 K
• 卷排序：5

文摘

Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment.ObjectivesTo evaluate the safety of alternative agents used in chronic urticaria.MethodsA retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed.ResultsAdverse effects were reported in 39 of 73 (53%) patients on dapsone, 19 of 47 (40%) patients on sulfasalazine, 15 of 36 (42%) patients on tacrolimus, 7 of 45 (16%) patients on hydroxychloroquine, 9 of 27 (33%) patients on mycophenolate, 6 of 8 (75%) patients on cyclosporine, and 3 of 24 (4%) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose.ConclusionsThe use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed.